Opioids and cancer recurrence

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 2, 2014, Pages 91-101

  Juneja, Rohit ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Immunomodulation; Metastasis; Morphine

Indexed keywords

MORPHINE; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT;

ANIMAL; CELLULAR IMMUNITY; COMPLICATION; DISEASE COURSE; HUMAN; IMMUNOCOMPROMISED PATIENT; METABOLISM; METASTASIS; NEOPLASM; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PHYSIOLOGY; PROCEDURES; REGIONAL ANESTHESIA; TUMOR RECURRENCE;

ANALGESICS, OPIOID; ANESTHESIA, CONDUCTION; ANIMALS; DISEASE PROGRESSION; HUMANS; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; MORPHINE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PAIN; PERIOPERATIVE PERIOD; RECEPTORS, OPIOID, MU;

EID: 84905824858     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000056     Document Type: Review

References (110)

1. Globocan 2012: Cancer Fact Sheet. Globocan 2012. http://globocan.iarc. fr/Pages/fact-sheets-cancer.aspx. Accessed 9 January 2014
2. Ripamonti CI. Pain management. Ann Oncol 2012; 23 (Suppl 1):294-301.
3. Kinsey DL. Effects of surgery upon cancer metastasis. JAMA 1961; 178:734-735.
4. Pollock RE, Lotzová E, Stanford SD. Mechanism of surgical stress impairment of human perioperative natural killer cell cytotoxicity. Arch Surg 1991; 126:338-342.
5. Desborough JP. The stress response to trauma and surgery. Br J Anaesth 2000; 85:109-117.
6. Mao L, Lin S, Lin J. The effects of anesthetics on tumor progression. Int J Physiol Pathophysiol Pharmacol 2013; 5:1-10.
7. Pool EH, Dunlop GR. Cancer cells in the blood stream. Am J Cancer 1934; 21:99-102.
8. Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001; 90:191-199.
9. Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain 2012; 6:11-16.
10. Afsharimani B, Cabot P, Parat M-O. Morphine and tumor growth and metastasis. Cancer Metastasis Rev 2011; 30:225-238.
11. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 133:571-573.
12. Tavare AN, Perry NJS, Benzonana LL, et al. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. Int J Cancer 2012; 130:1237-1250.
13. Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014; 27C:16-25.
14. SchreiberRD, Old LJ,Smyth MJ.Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-1570.
15. Schatten WE, Kramer WM. An experimental study of postoperative tumor metastases. II. Effects of anesthesia, operation, and cortisone administration on growth of pulmonary metastases. Cancer 1958; 11:460-462.
16. Weiss L. Cancer cell traffic from the lungs to the liver: an example of metastatic inefficiency. Int J Cancer 1980; 25:385-392.
17. Langley RR, Fidler IJ. The seed and soil hypothesis revisited: the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011; 128:2527-2535.
18. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 2012; 18:1201-1206.
19. Ji Y, Chen S, Xiao X, et al. b-blockers: a novel class of antitumor agents. Onco Targets Ther 2012; 5:391-401.
20. Retsky M, Demicheli R, Hrushesky WJM, et al. Reduction of breast cancer relapses with perioperative nonsteroidal anti-inflammatory drugs: new findings and a review. Curr Med Chem 2013; 20:4163-4176.
21. Neeman E, Zmora O, Ben-Eliyahu S. A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin Cancer Res 2012; 18:4895-4902.
22. Goldfarb Y, Sorski L, Benish M, et al. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg 2011; 253:798-810.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
24. Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010; 105:106-115.
25. Tai L-H, de Souza CT, Bélanger S, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res 2013; 73:97-107.
26. Shavit Y, Ben-Eliyahu S, Zeidel A, et al. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 2004; 11:255-260.
27. Ma J, Wang J, Wan J, et al. Morphine disrupts interleukin-23 (IL-23)/IL-17-mediated pulmonary mucosal host defense against Streptococcus pneumoniae infection. Infect Immun 2010; 78:830-837.
28. Sacerdote P, Manfredi B, Mantegazza P, et al. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997; 121:834-840.
29. Yeager MP, Procopio MA, DeLeo JA, et al. Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans. Anesth Analg 2002; 94:94-99; table of contents.
30. Beilin B, Shavit Y, Hart J, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg 1996; 82:492-497.
31. Page GG. Immunologic effects of opioids in the presence or absence of pain. J Pain Symptom Manage 2005; 29:S25-31.
32. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc 2011; 59:1899-1907.
33. Tabellini G, Borsani E, Benassi M, et al. Effects of opioid therapy on human natural killer cells. Int Immunopharmacol 2014; 18:169-174.
34. Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 2004; 110:385-392.
35. Franchi S, Panerai AE, Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun 2007; 21:767-774.
36. World Health Organization. Cancer pain relief. 2nd edn Geneva: World Health Organization; 1996; http://whqlibdoc.who.int/publications/9241544821.pdf [Accessed 28 December 2013]
37. Sacerdote P, Bianchi M, Gaspani L, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000; 90:1411-1414.
38. Gaspani L, Bianchi M, Limiroli E, et al. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol 2002; 129:18-24.
39. Forget P, Bentin C, Machiels J-P, et al. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth 2014. doi:10.1093/bja/aet464. [Epub ahead of print]
40. Galon J, Pagès F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10:1.
41. Beilin B, Shavit Y, Razumovsky J, et al. Effects of mild perioperative hypothermia on cellular immune responses. Anesthesiology 1998; 89:1133-1140.
42. Baumgartner JM, Silliman CC, Moore EE, et al. Stored red blood cell transfusion induces regulatory T cells. J Am Coll Surg 2009; 208:110-119.
43. Cata JP, Gottumukkala V, Sessler DI. How regional analgesia might reduce postoperative cancer recurrence. Eur J Pain Suppl 2011; 5:345-355.
44. Al-Hashimi M, Scott SWM, Thompson JP, et al. Opioids and immune modulation: more questions than answers. Br J Anaesth 2013; 111:80-88.
45. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3:453-458.
46. Ash SA, Buggy DJ. Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery? An update of available evidence. Best Pract Res Clin Anaesthesiol 2013; 27:441-456.
47. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62:4491-4498.
48. Singleton PA, Lingen MW, Fekete MJ, et al. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 2006; 72:3-11.
49. Tegeder I,Grösch S, Schmidtko A, et al.Gprotein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res 2003; 63:1846-1852.
50. Qin Y, Chen J, Li L, et al. Exogenous morphine inhibits human gastric cancer MGC-803 cell growth by cell cycle arrest and apoptosis induction. Asian Pac J Cancer Prev 2012; 13:1377-1382.
51. Koodie L, Ramakrishnan S, Roy S. Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. Am J Pathol 2010; 177:984-997.
52. Gach K, Wyrebska A, Szemraj J, et al. The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines. Mol Biol 2012; 46:796-801.
53. Deegan CA, Murray D, Doran P, et al. Anesthetic technique and the cytokine and matrix metalloproteinase response to primary breast cancer surgery. Reg Anesth Pain Med 2010; 35:490-495.
54. Afsharimani B, Baran J, Watanabe S, et al. Morphine and breast tumor metastasis: the role of matrix-degrading enzymes. Clin Exp Metastasis 2014; 31:149-158.
55. Mathew B, Lennon FE, Siegler J, et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011; 112:558-567.
56. Bortsov AV, Millikan RC, Belfer I, et al. m-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 2012; 116:896-902.
57. Wang S, Li Y, Liu X-D, et al. Polymorphism of A118G in m-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol 2013; 18:666-669.
58. Vuilleumier PH, Stamer UM, Landau R. Pharmacogenomic considerations in opioid analgesia. Pharmgenomics Pers Med 2012; 5:73-87.
59. Ribelles N, Santonja A, Pajares B, et al. The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. Cancer Treat Rev 2014; 40:293-299.
60. Weingaertner IR, Koutnik S, Ammer H. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network. PLoS One 2013; 8:e53510.
61. Forget P, Simonet O, De Kock M. Cancer surgery induces inflammation, immunosuppression and neo-angiogenesis, but is it influenced by analgesics? F1000 Research 2013; 2:102.
62. Farooqui M, Geng ZH, Stephenson EJ, et al. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther 2006; 5:611-620.
63. Parat MO. Morphine and metastasis: from bench to bedside. In: Parat MO, editor. Morphine and metastasis SE -1. Netherlands: Springer; 2013. pp. 1-13.
64. Barnett V, Twycross R, Mihalyo M, et al. Opioid antagonists. J Pain Symptom Manage 2014; 47:341-352.
65. McLaughlin PJ, Zagon IS. Novel treatment for triple-negative breast and ovarian cancer: endogenous opioid suppression of women's cancers. Expert Rev Anticancer Ther 2014; 14:247-250.
66. Sobczak M, Saaga M, Storr MA, et al. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol 2014; 49:24-45.
67. Eisenstein TK, Rahim RT, Feng P, et al. Effects of opioid tolerance and withdrawal on the immune system. J Neuroimmune Pharmacol 2006; 1:237-249.
68. Exadaktylos AK, Buggy DJ, Moriarty DC, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006; 105:660-664.
69. Biki B, Mascha E, Moriarty DC, et al. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology 2008; 109:180-187.
70. Wuethrich PY, Hsu Schmitz S-F, Kessler TM, et al. Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: a retrospective study. Anesthesiology 2010; 113:570-576.
71. Gupta A, Björnsson A, Fredriksson M, et al. Reduction in mortality after epidural anaesthesia and analgesia in patients undergoing rectal but not colonic cancer surgery: a retrospective analysis of data from 655 patients in central Sweden. Br J Anaesth 2011; 107:164-170.
72. Hiller JG, Hacking MB, Link EK, et al. Perioperative epidural analgesia reduces cancer recurrence after gastro-oesophageal surgery. Acta Anaesthesiol Scand 2014. doi:10.1111/aas.12255. [Epub ahead of print]
73. De Oliveira GS, Ahmad S, Schink JC, et al. Intraoperative neuraxial anesthesia but not postoperative neuraxial analgesia is associated with increased relapse-free survival in ovarian cancer patients after primary cytoreductive surgery. Reg Anesth Pain Med 2011; 36:271-277.
74. Christopherson R, James KE, Tableman M, et al. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg 2008; 107:325-332.
75. Binczak M, Tournay E, Billard V, et al. Major abdominal surgery for cancer: does epidural analgesia have a long-term effect on recurrence-free and overall survival? Ann Fr Anesth Reanim 2013; 32:e81-e88.
76. Myles PS, Peyton P, Silbert B, et al. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial. BMJ 2011; 342:d1491.
77. Wuethrich PY, Thalmann GN, Studer UE, et al. Epidural analgesia during open radical prostatectomy does not improve long-term cancer-related outcome: a retrospective study in patients with advanced prostate cancer. PLoS One 2013; 8:e72873.
78. Tsui BCH, Rashiq S, Schopflocher D, et al. Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Can J Anaesth 2010; 57:107-112.
79. Cummings KC, Xu F, Cummings LC, et al. A comparison of epidural analgesia and traditional pain management effects on survival and cancer recurrence after colectomy: a population-based study. Anesthesiology 2012; 116:797-806.
80. Day A, Smith R, Jourdan I, et al. Retrospective analysis of the effect of postoperative analgesia on survival in patients after laparoscopic resection of colorectal cancer. Br J Anaesth 2012; 109:185-190.
81. Gottschalk A, Ford JG, Regelin CC, et al. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology 2010; 113:27-34.
82. Chen WK, Miao CH. The effect of anesthetic technique on survival in human cancers: a meta-analysis of retrospective and prospective studies. PLoSOne 2013; 8:e56540.
83. Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 2013; 119:4103-4110.
84. Scavonetto F, Yeoh TY, Umbreit EC, et al. Association between neuraxial analgesia, cancer progression, and mortality after radical prostatectomy: a large, retrospective matched cohort study. Br J Anaesth 2013. doi:10.1093/ bja/aet467. [Epub ahead of print]
85. O'Connor PJ, Paul J, Hanson, et al. Induced hypotension with epidural/ general anesthesia reduces transfusion in radical prostate surgery. Can J Anaesth 2006; 53:873-880.
86. Rigg JRA, Jamrozik K, Myles PS, et al. Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial. Lancet 2002; 359:1276-1282.
87. Chen M, Huang J, Zhu Z, et al. Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer 2013; 13:539.
88. Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth 2012; 109 (Suppl):i17-i28.
89. Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults. (CG140). National Institute for Health and Care Excellence2012. http://www.nice.org.uk/CG140. Accessed 05 January 2014
90. Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23 (Suppl 7):vii139-vii154.
91. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13:e58-68.
92. Vignaroli E, Bennett MI, Nekolaichuk C, et al. Strategic pain management: the identification and development of the IAHPC opioid essential prescription package. J Palliat Med 2012; 15:186-191.
93. Yeager MP, Colacchio TA, Yu CT, et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995; 83:500-508.
94. Page GG, McDonald JS, Ben-Eliyahu S. Preoperative versus postoperative administration of morphine: impact on the neuroendocrine, behavioural, and metastatic-enhancing effects of surgery. Br J Anaesth 1998; 81:216-223.
95. Sasamura T, Nakamura S, Iida Y, et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol 2002; 441:185-191.
96. Drewes AM, Jensen RD, Nielsen LM, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol 2013; 75:60-78.
97. Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet 1993; 341:1075-1076.
98. Santini D, Lanzetta G, Dell'Aquila E, et al. Old' and 'new' drugs for the treatment of cancer pain. Expert Opin Pharmacother 2013; 14:425-433.
99. Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19:1985-1991.
100. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin 2011; 61:157-182.
101. Do opioids influence cancer growth? The IAHPC perspective. EAPC2012. http://eapcnet.wordpress.com/2012/03/30/do-opioids-influence-cancergrowth-the- iahpc-perspective-3/. Accessed 5 January 2014
102. Clarke H, Soneji N, Ko DT, et al. Rates and risk factors for prolonged opioid use after major surgery: population based cohort study. BMJ 2014; 348:g1251.
103. Mitra R, Jones S. Adjuvant analgesics in cancer pain: a review. Am J Hosp Palliat Care 2012; 29:70-79.
104. Rawal N. Epidural technique for postoperative pain: gold standard no more? Reg Anesth Pain Med 2012; 37:310-317.
105. Halabi WJ, Kang CY, Nguyen VQ, et al. Epidural analgesia in laparoscopic colorectal surgery: a nationwide analysis of use and outcomes. JAMA Surg 2014; 149:130-136.
106. Zeppetella G. Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Compr Canc Netw 2013; 11 (Suppl 1):S37-43.
107. Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane database Syst Rev 2013; 10:CD004311.
108. Gibbins J, Bhatia R, Forbes K, et al. What do patients with advanced incurable cancer want from the management of their pain? A qualitative study Palliat Med 2014; 28:71-78.
109. WHO Fact Sheet No.297. Cancer. Geneva: World Health Organization; 2014. http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 22 February 2014
110. Manglik A, Kruse AC, Kobilka TS, et al. Crystal structure of the m-opioid receptor bound to a morphinan antagonist. Nature 2012; 485:321-326.